Pharmacological Modulation of GABA Function in Autism Spectrum Disorders: A Systematic Review of Human Studies

Journal of Autism and Developmental Disorders

Volumn 46, Issue 3, 2016, Pages 825-839

  Brondino, Natascia ^a   Fusar Poli, Laura ^a   Panisi, Cristina ^a   Damiani, Stefano ^a   Barale, Francesco ^a   Politi, Pierluigi ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Autism spectrum disorder; Clinical trials; GABA; Systematic review

Indexed keywords

4 AMINOBUTYRIC ACID; BENZODIAZEPINE RECEPTOR AFFECTING AGENT;

AUTISM SPECTRUM DISORDER; HUMAN; METABOLISM;

AUTISM SPECTRUM DISORDER; GABA MODULATORS; GAMMA-AMINOBUTYRIC ACID; HUMANS;

EID: 84957843236     PISSN: 01623257     EISSN: 15733432     Source Type: Journal    
DOI: 10.1007/s10803-015-2619-y     Document Type: Article

References (93)

1. Abrahams, B. S., & Geschwind, D. H. (2008). Advances in autism genetics: On the threshold of a new neurobiology. Nature Reviews Genetics,9, 341–355.
2. Abu Shmais, G. A., Al-Ayadhi, L. Y., Al-Dbass, A. M., & El-Ansary, A. K. (2012). Mechanism of nitrogen metabolism-related parameters and enzyme activities in the pathophysiology of autism. Journal of Neurodevelopmental Disorders,4(1), 4.
3. Alabdali, A., Al-Ayadhi, L., & El-Ansary, A. (2014). Association of social and cognitive impairment and biomarkers in autism spectrum disorders. Journal of Neuroinflammation,8(11), 4.
4. Amaral, D. G., Schumann, C. M., & Nordahl, C. W. (2008). Neuroanatomy of autism. Trends in Neurosciences,31, 137–145.
5. Banerjee, A., García-Oscos, F., Roychowdhury, S., Galindo, L. C., Hall, S., Kilgard, M. P., et al. (2013). Impairment of cortical GABAergic synaptic transmission in an environmental rat model of autism. International Journal of Neuropsychopharmacology,16, 1309–1810.
6. Bauman, M. L., & Kemper, T. L. (2005). Neuroanatomic observations of the brain in autism: A review and future directions. International Journal of Developmental Neuroscience,23, 183–187.
7. Berg, A. T., Plioplys, S., & Tuchman, R. (2011). Risk and correlates of autism spectrum disorders in children with epilepsy: A community based study. Journal of Child Neurology,26, 540–547.
8. Berry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., et al. (2012). Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Science Translational Medicine,4(152), 152ra127.
9. Blatt, G. J., Fitzgerald, C. M., Guptill, J. T., Booker, A. B., Kemper, T. L., & Bauman, M. L. (2001). Density and distribution of hippocampal neurotransmitter receptors in autism: An autoradiographic study. Journal of Autism and Developmental Disorders,31, 537–543.
10. Brogden, R. N., & Goa, K. L. (1991). Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine. Drugs,42, 1061–1089.
11. Bu, D. F., Erlander, M. G., Hitz, B. C., Tillakaratne, N. J., Kaufman, D. L., Wagner-McPherson, C. B., et al. (1992). Two human glutamate decarboxylase, 65 kDa GAD and 67 kDa GAD, are each encoded by a single gene. Proceedings of the National Academy of Sciences of the United States of America,89, 2115–2119.
12. Buxbaum, J. D., Silverman, J. M., Smith, C. J., Greenberg, D. A., Kilifarski, M., Reichert, J., et al. (2002). Association between a GABRB3 polymorphism and autism. Molecular Psychiatry,7, 311–316.
13. Casanova, M. F., van Kooten, I. A., Switala, A. E., van Engeland, H., Heinsen, H., Steinbusch, H. W., et al. (2006). Minicolumnar abnormalities in autism. Acta Neuropathologica,112(3), 287–303.
14. CDC. (2014). Prevalence of autism spectrum disorders among children aged 8 years—Autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR,63(SS02), 1–21.
15. Cellot, G., & Cherubini, E. (2014). GABAergic signaling as therapeutic target for autism spectrum disorders. Frontiers in Pediatrics,8(2), 70.
16. Chakrabarti, S., & Fombonne, E. (2005). Pervasive developmental disorders in preschool children: Confirmation of high prevalence. American Journal of Psychiatry,162, 1133–1141.
17. Cheh, M. A., Millonig, J. H., Roselli, L. M., Ming, X., Jacobsen, E., Kamdar, S., et al. (2006). En2 knockout mice display neurobehavioral and neurochemical alterations relevant to autism spectrum disorder. Brain Research,1116, 166–176.
18. Chez, M. G., Buchanan, C. P., Aimonovitch, M. C., Becker, M., Schaefer, K., Black, C., et al. (2002). Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. Journal of Child Neurology,17, 833–837.
19. Coghlan, S., Horder, J., Inkster, B., Mendez, M. A., Murphy, D. G., & Nutt, D. J. (2012). GABA system dysfunction in autism and related disorders: From synapse to symptoms. Neuroscience and Biobehavioral Reviews,36(9), 2044–2055.
20. DeLorey, T. M., Sahbaie, P., Hashemi, E., Homanics, G. E., & Clark, J. D. (2008). Gabrb3 gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: A potential model of autism spectrum disorder. Behavioural Brain Research,187, 207–220.
21. Dhossche, D., Applegate, H., Abraham, A., Maertens, P., Bland, L., Bencsath, A., et al. (2002). Elevated plasma gammaaminobutyric acid (GABA) levels in autistic youngsters: stimulus for a GABA hypothesis of autism. Medical Science Monitor,8, R1–R6.
22. Eftekhari, S., Mehvari Habibabadi, J., Najafi Ziarani, M., Hashemi Fesharaki, S. S., Gharakhani, M., Mostafavi, H., et al. (2013). Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy. Epilepsia,54(1), e9–e12.
23. El-Ansary, A., & Al-Ayadhi, L. (2014). GABAergic/glutamatergic imbalance relative to excessive neuroinflammation in autism spectrum disorders. Journal of Neuroinflammation,11(1), 189.
24. El-Ansary, A. K., Bacha, A. B., & Ayahdi, L. Y. (2011). Relationship between chronic lead toxicity and plasma neurotransmitters in autistic patients from Saudi Arabia. Clinical Biochemistry,44(13), 1116–1120.
25. Erickson, C. A., Early, M., Stigler, K. A., Wink, L. K., Mullett, J. E., & McDougle, C. J. (2011). An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. Journal of Child and Adolescent Psychopharmacology,21, 565–569.
26. Erickson, C. A., Mullett, J. E., & McDougle, C. J. (2010). Brief report: Acamprosate in fragile X syndrome. Journal of Autism and Developmental Disorders,40, 1412–1416.
27. Erickson, C. A., Veenstra-Vanderweele, J. M., Melmed, R. D., McCracken, J. T., Ginsberg, L. D., Sikich, L., et al. (2014a). STX209 (Arbaclofen) for autism spectrum disorders: An 8-week open-label study. Journal of Autism and Developmental Disorders,44(4), 958–964.
28. Erickson, C. A., Wink, L. K., Early, M. C., Stiegelmeyer, E., Mathieu-Frasier, L., Patrick, V., et al. (2014b). Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder. Journal of Autism and Developmental Disorders,44, 981–987.
29. Erickson, C. A., Wink, L. K., Ray, B., Early, M. C., Stiegelmeyer, E., Mathieu-Frasier, L., et al. (2013). Impact of acamprosate on behavior and brain-derived neurotrophic factor: An open-label study in youth with fragile X syndrome. Psychopharmacology (Berlin),228, 75–84.
30. Fatemi, S. H., Folsom, T. D., Reutiman, T. J., & Thuras, P. D. (2009a). Expression of GABAB receptors is altered in brains of subjects with autism. Cerebellum,8, 64–69.
31. Fatemi, S. H., Halt, A. R., Stary, J. M., Kanodia, R., Schulz, S. C., & Realmuto, G. R. (2002). Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in parietal and cerebellar cortices of autistic subjects. Biological Psychiatry,52, 805–810.
32. Fatemi, S. H., Reutiman, T. J., Folsom, T. D., Rooney, R. J., Patel, D. H., & Thuras, P. D. (2010). mRNA and protein levels for GABAAalpha4, alpha5, beta1 and GABABR1 receptors are altered in brains from subjects with autism. Journal of Autism and Developmental Disorders,40, 743–750.
33. Fatemi, S. H., Reutiman, T. J., Folsom, T. D., Rustan, O. G., Rooney, R. J., & Thuras, P. D. (2014). Downregulation of GABAA receptor protein subunits α6, β2, δ, ε, γ2, θ, and ρ2 in the superior frontal cortex of subjects with autism. Journal of Autism and Developmental Disorders,44(8), 1833–1845.
34. Fatemi, S. H., Reutiman, T. J., Folsom, T. D., & Thuras, P. D. (2009b). GABA (A) receptor down regulation in brains of subjects with autism. Journal of Autism and Developmental Disorders,39, 223–230.
35. Földy, C., Malenka, R. C., & Südhof, T. C. (2013). Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling. Neuron,78, 498–509.
36. Fombonne, E., Zakarian, R., Bennett, A., Meng, L., & McLean-Heywood, D. (2006). Pervasive developmental disorders in Montreal, Quebec, Canada: Prevalence and links with immunizations. Pediatrics,118, e139–e150.
37. Frizzo, M. E., Dall’Onder, L. P., Dalcin, K. B., & Souza, D. O. (2004). Riluzole enhances glutamate uptake in rat astrocyte cultures. Cellular and Molecular Neurobiology,24(1), 123–128.
38. Ghaleiha, A., Mohammadi, E., Mohammadi, M. R., Farokhnia, M., Modabbernia, A., Yekehtaz, H., et al. (2013). Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: A double-blind, placebo-controlled, randomized trial. Paediatric Drugs,15(6), 505–514.
39. Guptill, J. T., Booker, A. B., Gibbs, T. T., Kemper, T. L., Bauman, M. L., & Blatt, G. J. (2007). [3H]-flunitrazepam-labeled benzodiazepine binding sites in the hippocampal formation in autism: A multiple concentration autoradiographic study. Journal of Autism and Developmental Disorders,37, 911–920.
40. Hadjikhani, N., Zürcher, N. R., Rogier, O., Ruest, T., Hippolyte, L., Ben-Ari, Y., et al. (2015). Improving emotional face perception in autism with diuretic bumetanide: A proof-of-concept behavioral and functional brain imaging pilot study. Autism,19(2), 149–157.
41. Harada, M., Taki, M. M., Nose, A., Kubo, H., Mori, K., Nishitani, H., et al. (2011). Non-invasive evaluation of the GABAergic/glutamatergic system in autistic patients observed by MEGA-editing proton MR spectroscopy using a clinical 3 Tesla instrument. Journal of Autism and Developmental Disorders,41, 447–454.
42. He, Y., Benz, A., Fu, T., Wang, M., Covey, D. F., Zorumski, C. F., et al. (2002). Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function. Neuropharmacology,42(2), 199–209.
43. Hellings, J. A., Weckbaugh, M., Nickel, E. J., Cain, S. E., Zarcone, J. R., Reese, R. M., et al. (2005). A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol,15(4), 682–692.
44. Henderson, C., Wijetunge, L., Kinoshita, M. N., Shumway, M., Hammond, R. S., Postma, F. R., et al. (2012). Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Science Translational Medicine,4(152), 152ra128.
45. Higgins, J. P. T., & Green, S. (Eds.). (2011). Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration.
46. Hogart, A., Nagarajan, R. P., Patzel, K. A., Yasui, D. H., & Lasalle, J. M. (2007). 15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders. Human Molecular Genetics,16, 691–703.
47. Hollander, E., Chaplin, W., Soorya, L., Wasserman, S., Novotny, S., Rusoff, J., et al. (2010). Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology,35, 990–998.
48. Hollander, E., Soorya, L., Wasserman, S., Esposito, K., Chaplin, W., & Anagnostou, E. (2006). Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. International Journal of Neuropsychopharmacology,9, 209–213.
49. Hussman, J. P. (2001). Suppressed GABAergic inhibition as a common factor in suspected etiologies of autism. Journal of Autism and Developmental Disorders,31, 247–248.
50. Kalk, N. J., & Lingford-Hughes, A. R. (2014). The clinical pharmacology of acamprosate. British Journal of Clinical Pharmacology,77(2), 315–323.
51. Kaupmann, K., Schuler, V., Mosbacher, J., Bischoff, S., Bittiger, H., Heid, J., et al. (1998). Human γ-aminobutyric acid type B receptors are differentially expressed and regulate inwardly rectifying K+ channels. Proceedings of the National Academy of Sciences of the United States of America,95, 14991–14996.
52. Kim, H. L., Donnelly, J. H., Tournay, A. E., Book, T. M., & Filipek, P. (2006a). Absence of seizures despite high prevalence of epileptiform EEG abnormalities in children with autism monitored in a tertiary care center. Epilepsia,47(2), 394–398.
53. Kim, S. A., Kim, J. H., Park, M., Cho, I. H., & Yoo, H. J. (2006b). Association of GABRB3 polymorphisms with autism spectrum disorders in Korean trios. Neuropsychobiology,54, 160–165.
54. Kuriyama, K., Hirouchi, M., & Kimura, H. (2000). Neurochemical and molecular pharmacological aspects of the GABA(B) receptor. Neurochemical Research,25, 1233–1239.
55. Lal, R., Sukbuntherng, J., Tai, E. H., Upadhyay, S., Yao, F., Warren, M. S., et al. (2009). Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. Journal of Pharmacology and Experimental Therapeutics,330(3), 911–921.
56. Lawrence, Y. A., Kemper, T. L., Bauman, M. L., & Blatt, G. J. (2010). Parvalbumin-, calbindin-, and calretinin-immunoreactive hippocampal interneuron density in autism. Acta Neurologica Scandinavica,121, 99–108.
57. Lemonnier, E., & Ben-Ari, Y. (2010). The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects. Acta Paediatrica,99, 1885–1888.
58. Lemonnier, E., Degrez, C., Phelep, M., Tyzio, R., Josse, F., Grandgeorge, M., et al. (2012). A randomised controlled trial of bumetanide in the treatment of autism in children. Translational Psychiatry,2, e202.
59. Levy, S. E., Mandell, D. S., & Schultz, R. T. (2009). Autism. The Lancet,374, 1627–1638.
60. Löscher, W. (1981). Effect of inhibitors of GABA aminotransferase on the metabolism of GABA in brain tissue and synaptosomal fractions. Journal of Neurochemistry Research,36, 1521–1527.
61. Löscher, W. (2002). Basic pharmacology of valproate: A review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs,16(10), 669–694.
62. Ma, D. Q., Whitehead, P. L., Menold, M. M., Martin, E. R., Ashley-Koch, A. E., Mei, H., et al. (2005). Identification of significant association and gene–gene interaction of GABA receptor subunit genes in autism. American Journal of Human Genetics,77, 377–388.
63. Martin, D., Thompson, M. A., & Nadler, J. V. (1993). The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. European Journal of Pharmacology,250(3), 473–476.
64. Mendez, M. A., Horder, J., Myers, J., Coghlan, S., Stokes, P., Erritzoe, D., et al. (2013). The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography study. Neuropharmacology,68, 195–201.
65. Mori, T., Mori, K., Fujii, E., Toda, Y., Miyazaki, M., Harada, M., et al. (2012). Evaluation of the GABAergic nervous system in autistic brain: (123)I-iomazenil SPECT study. Brain Development,34, 648–654.
66. Mott, D. D., & Lewis, D. V. (1994). The pharmacology and function of central GABAB receptors. International Review of Neurobiology,36, 97–223.
67. NCT01288716. http://www.clinicaltrials.gov/ct2/show/NCT01288716
68. NCT01706523. http://www.clinicaltrials.gov/ct2/show/NCT01706523
69. NCT01813318. http://www.clinicaltrials.gov/ct2/show/NCT01813318
70. NCT01966679.https://www.clinicaltrials.gov/ct2/show/NCT01966679
71. NCT02094651. http://www.clinicaltrials.gov/ct2/show/NCT02094651
72. Nutt, D. J., & Malizia, A. L. (2001). New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. British Journal of Psychiatry,179, 390–396.
73. Oblak, A., Gibbs, T. T., & Blatt, G. J. (2009). Decreased GABAA receptors and benzodiazepine binding sites in the anterior cingulate cortex in autism. Autism Research,2, 205–219.
74. Pizzarelli, R., & Cherubini, E. (2013). Developmental regulation of GABAergic signalling in the hippocampus of neuroligin 3 R451C knock-in mice: an animal model of autism. Frontiers in Cellular Neuroscience,4(7), 85.
75. Rimvall, K., & Martin, D. L. (1994). The level of GAD67 protein is highly sensitive to small increases in intraneuronal γ-aminobutyric acid levels. Journal of Neurochemistry,62, 1375–1381.
76. Ritvo, E. R., Freeman, B. J., Scheibel, A. B., Duong, T., Robinson, H., Guthrie, D., et al. (1986). Lower Purkinje cell counts in the cerebella of four autistic subjects: initial findings of the UCLANSAC autopsy research report. American Journal of Psychiatry,146, 862–866.
77. Rojas, D. C., Singel, D., Steinmetzm, S., Hepburn, S., & Brown, M. S. (2014). Decreased left perisylvian GABA concentration in children with autism and unaffected siblings. Neuroimage,86, 28–34.
78. Rolf, L. H., Haarmann, F. Y., Grotemeyer, K. H., & Kehrer, H. (1993). Serotonin and amino acid content in platelets of autistic children. Acta Psychiatrica Scandinavica,87, 312–316.
79. Russo, A. J. (2013). Correlation between hepatocyte growth factor (HGF) and gamma-aminobutyric acid (GABA) plasma levels in autistic children. Biomark Insights,12(8), 69–75.
80. Sawaya, M. C. B., Horton, R. W., & Meldrun, B. S. (1975). Effects of anticonvulsant drugs on the cerebral enzymes metabolizing GABA. Epilepsia,16, 649–655.
81. Sgadò, P., Genovesi, S., Kalinovsky, A., Zunino, G., Macchi, F., Allegra, M., et al. (2013). Loss of GABAergic neurons in the hippocampus and cerebral cortex of engrailed-2 null mutant mice: Implications for autism spectrum disorders. Experimental Neurology,247, 496–505.
82. Sieghart, W., & Sperk, G. (2002). Subunit composition, distribution and function of GABA(A) receptor subtypes. Current Topics in Medicinal Chemistry,2, 795–816.
83. Stell, B. M., Brickley, S. G., Tang, C. Y., Farrant, M., & Mody, I. (2003). Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors. Proceedings of the National Academy of Sciences of the United States of America,100(24), 14439–14444.
84. Tabuchi, K., Blundell, J., Etherton, M. R., Hammer, R. E., Liu, X., Powell, C. M., et al. (2007). A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice. Science,318, 71–76.
85. Trombley, P. Q., Horning, M. S., & Blakemore, L. J. (1998). Carnosine modulates zinc and copper effects on amino acid receptors and synaptic transmission. NeuroReport,9(15), 3503–3507.
86. Tuchman, R., & Rapin, I. (2002). Epilepsy in autism. Lancet Neurology,1(6), 352–358.
87. van Kooten, I. A., Palmen, S. J., von Cappeln, P., Steinbusch, H. W., Korr, H., Heinsen, H., et al. (2008). Neurons in the fusiform gyrus are fewer and smaller in autism. Brain,131, 987–999.
88. Veenstra-VanderWeele, J., Sikich, L., Melmed, R., von Hehn, J. S., Walton-Bowen, K. L., & Kuriyama, N. et al. (2013). Randomized, controlled, phase 2 trial of STX209 for social function in ASD. Abstract presented at the IMFAR meeting 2013.
89. Weiss, M., Tikhonov, D., & Buldakova, S. (2002). Effect of flumazenil on GABAA receptors in isolated rat hippocampal neurons. Neurochemical Research,7(12), 1605–1612.
90. Wolpert, C. M., Menold, M. M., Bass, M. P., Qumsiyeh, M. B., Donnelly, S. L., Ravan, S. A., et al. (2000). Three probands with autistic disorder and isodicentric chromosome 15. American Journal of Medical Genetics,96, 365–372.
91. Wray, J. A., Yoon, J. H., Vollmer, T., & Mauk, J. (2000). Pilot study of the behavioral effects of flumazenil in two children with autism. Journal of Autism and Developmental Disorders,30, 619–620.
92. Yip, J., Soghomonian, J. J., & Blatt, G. J. (2007). Decreased GAD67 mRNA levels in cerebellar Purkinje cells in autism: Pathophysiological implications. Acta Neuropathologica,113, 559–568.
93. Yip, J., Soghomonian, J. J., & Blatt, G. J. (2009). Decreased GAD65 mRNA levels in select subpopulations of neurons in the cerebellar dentate nuclei in autism: An in situ hybridization study. Autism Research,2, 50–59.